Horizon Pharma Announces the U.S. Patent and Trademark

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering VIMOVO(R) (Naproxen / Esomeprazole) Delayed Release Tablets

DEERFIELD, IL--(Marketwired - Aug 5, 2014) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that POZEN Inc. ( NASDAQ : POZN ) has received two Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application numbers 14/231,971, and 14/244,471, entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that cover Horizon and POZEN'S U.S. approved product VIMOVO® (naproxen / esomeprazole magnesium) delayed release tablets.

"The claims included in these Notices of Allowance further bolster the already robust VIMOVO patent estate," stated Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "This puts us in an even stronger position to protect VIMOVO in the U.S. and to ensure that we are able to continue to make this important therapy available to patients."

These Notices of Allowance conclude the substantive examination of the patent applications and are expected to result in the issuance of U.S. patents after administrative processes are completed. The U.S. patents scheduled to issue from these applications will expire in 2022. After issuance, Horizon and POZEN plan to list the U.S. patent issued from U.S. patent application number 14/244,471 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Once issued, this will be the ninth U.S. patent to be listed in the Orange Book for VIMOVO. The U.S. patent to issue from U.S. patent application 14/231,971, while not eligible to be listed in the Orange Book, will cover the process for preparing VIMOVO.

About Horizon Pharma

Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS ® , VIMOVO ® and RAYOS ® /LODOTRA ® , which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines or companies where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com .

About VIMOVO®

VIMOVO ® (naproxen / esomeprazole magnesium) is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is not recommended for use in children younger than 18 years of age. VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products. Controlled studies do not extend beyond six months. VIMOVO should be used at the lowest dose and for the shortest amount of time as directed by your health care provider.

For Full Prescribing Information see www.VIMOVO.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the issuance of patents based on the Notices of Allowance from the U.S. Patent and Trademark Office, the ability to continue making VIMOVO available to patients, the ability to protect the innovation and commercial potential of VIMOVO and plans to list newly issued patents in the FDA's Orange Book. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether the administrative processes required for the issuance of patents as indicated in the Notices of Allowance will be completed in a timely matter or at all, whether the patents, if issued as indicated in the Notices of Allowance, will provide sufficient protection and market exclusivity for VIMOVO, whether any patents covering VIMOVO may be challenged, invalidated, infringed or circumvented by third parties and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contact: Robert F. Carey Executive Vice President and Chief Business Officer Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 29

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 166

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 89

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 101

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 93

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 74

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading

Top 5 Most Recently Viewed Articles

Xometry Prepares for Financial Report Ahead of Market Opening

Updated Category News Views 175

Xometry Financial Results Announcement Overview Xometry, Inc. (NASDAQ: XMTR), recognized as a leading AI-powered marketplace for manufacturing services, is gearing up to announce its fourth quarter and full year 2024 financial results. The report is expected to be made available before trading opens on the market. This announcement represents a significant opportunity for...

Continue Reading
Warren Buffett's Surprising Bet on the RV Industry Pays Off

Updated Category News Views 1216

Warren Buffett's Unconventional Investment Journey Warren Buffett, known for his wisdom in investing, made a surprising decision that changed the game for Berkshire Hathaway Inc. He chose to invest in Forest River, an RV manufacturer, despite having little knowledge of the industry. This significant move, spearheaded by the late founder Pete Liegl, proved to be highly...

Continue Reading
BizClik Media Unveils September Editions of Key Industry Magazines

Updated Category News Views 201

BizClik Media Unveils September Editions of Key Publications This September, the latest editions of Supply Chain Digital, Procurement Magazine, and Manufacturing Digital have been published, featuring engaging interviews with industry leaders and experts from prominent companies. Spotlighting Industry Leaders This month's issues highlight a variety of thought-provoking...

Continue Reading
Ascletis Unveils Breakthrough Findings for ASC30 Injection

Updated Category News Views 210

Exciting Developments in Obesity Treatment with ASC30 In the realm of obesity management, Ascletis Pharma Inc. has made significant strides with their investigational drug ASC30, a promising GLP-1 receptor (GLP-1R) agonist designed for both oral and subcutaneous use. Preliminary results from their Phase Ib trial conducted in the U.S. indicate a fascinating half-life of 36...

Continue Reading
CBIZ Welcomes Kathy Raffa to Its Board of Directors

Updated Category News Views 204

CBIZ Strengthens Board with New Appointment CBIZ, Inc. (NYSE: CBZ), a prominent national professional services advisor, has recently announced the addition of Kathy Raffa to its Board of Directors. This strategic appointment, effective January 15, 2025, follows CBIZ's recent acquisition of the non-attest assets of Marcum. This move is seen as a testament to the...

Continue Reading